-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Wet (Neovascular/Exudative) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Wet Macular Degeneration Clinical Trial Report Overview A total of 853 wet macular degeneration clinical trials were conducted as of April 2024. The wet macular degeneration clinical trial report provides a comprehensive understanding of the wet macular degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions...
-
Sector Analysis
Fuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Report Overview Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, slowly progressive, often asymmetric corneal disease. FECD is a sporadic or autosomal dominant dystrophy involving the endothelial layer of the cornea. Key Mechanisms of Action (Pipeline) · Enzyme Inhibitor · Receptor Agonist · Protein and Peptide Inhibitor · Transporter Inhibitor Key Molecule Types (Pipeline) · Small Molecule · Biologic Key Routes of Administration (Pipeline) · Topical · Oral · Injection Top Sponsors...
-
Sector Analysis
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Product Insights
Keratoconjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Keratoconjunctivitis Clinical Trials Overview The Keratoconjunctivitis clinical trial report consists of 1391 trials. The report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Keratoconjunctivitis are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report. Key Regions · Asia-Pacific · Europe · North America · ...
-
Product Insights
Allergic Rhino-Conjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Allergic Rhino-Conjunctivitis Clinical Trials Market Report Overview The Allergic Rhino-Conjunctivitis clinical trial market research report provides an overview of the Allergic Rhino-Conjunctivitis clinical trials scenario. This report provides top-line data relating to the clinical trials on Allergic Rhino-Conjunctivitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Sector Analysis
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Overview JMD, also called juvenile macular dystrophy, is a group of inherited eye disorders that affects children and young adults, disturbing their central vision. JMD is classified into three major types: Stargardt disease, X-linked retinoschisis (juvenile retinoschisis), and Best vitelliform macular dystrophy (Best’s disease). In the 16MM (Australia, Brazil, China, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, and the US), epidemiologists estimate there were around...
-
Product Insights
Age Related Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Age-Related Macular Degeneration Clinical Trials Market Report Overview There were a total of 1458 age-related macular degeneration clinical trials conducted as of July 2023. The age-related macular degeneration clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Age-Related...
-
Product Insights
Choroidal Neovascularization Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Choroidal Neovascularization Clinical Trials Market Overview The Choroidal Neovascularization clinical trial market research report provides an overview of the Choroidal Neovascularization Clinical trials scenario. This report provides top-line data relating to the clinical trials on Choroidal Neovascularization and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It...
-
Sector Analysis
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Report Overview Allergic conjunctivitis (AC) is an inflammatory response of the conjunctiva to an allergen or irritant such as pollen, dust, and mold. It is part of a larger systemic atopic reaction and is usually seasonal, with associated upper respiratory tract symptoms and complaints of redness and swelling of the conjunctiva, with severe itching and increased lacrimation. It has been estimated that that the highest diagnosed prevalence of AC will be in China,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.